During the past few years, many experts have suggested that bipolar disorder — a serious illness resulting in significant psychosocial morbidity and excess mortality — is under-recognized, particularly in patients with major depression. Even patients who are diagnosed with bipolar disorder often wait more than 10 years after initially seeking treatment for the correct diagnosis to be made.
The clinical implications of the failure to recognize bipolar disorder in depressed patients include the under-prescription of mood-stabilizing medications, and an increased risk of rapid “cycling” — swings between manic and depressive phases. But, perhaps as a consequence of concerted efforts to improve the recognition of bipolar disorder, during the past few years we have observed the emergence of an opposite phenomenon — overdiagnosis.
In my own practice, my colleagues and I have encountered patients who reported that they were previously diagnosed with bipolar disorder, despite lacking a history of manic or hypomanic episodes. To be sure, we have also seen patients seeking treatment for depression who really did have bipolar disorder. However, there seemed to be more overdiagnosis than underdiagnosis.
We therefore conducted a study to examine empirically how often bipolar disorder might be over- and under-diagnosed. Seven hundred psychiatric outpatients were interviewed with the Structured Clinical Interview for DSM-IV (SCID) and completed a self-administered questionnaire that asked whether they had been previously diagnosed by a health-care professional with bipolar or manic-depressive disorder. Family history information was obtained from the patient regarding their immediate relatives.
Slightly more than 20 percent (145 patients) in our sample reported that they had been previously diagnosed as having bipolar disorder, significantly higher than the 12.9 percent rate based on the SCID. Less than half of those who reported that they had been previously diagnosed with bipolar disorder were diagnosed with bipolar disorder based on the SCID. Patients with SCID-diagnosed bipolar disorder had a significantly higher risk of bipolar disorder in their immediate family members than patients who self-reported a previous diagnosis of bipolar disorder that was not confirmed by the SCID. Patients who self-reported a previous diagnosis of bipolar disorder that was not confirmed by the SCID did not have a significantly higher risk for bipolar disorder than the patients who were negative for bipolar disorder by self-report and the SCID. Our findings, validated by family history, thus suggest that bipolar disorder was overdiagnosed.
Any study seeking to determine whether a psychiatric disorder is over-diagnosed will find that some patients with the condition do not have it upon re-interview. Such is the nature of the imperfect reliability of psychiatric diagnosis. The question, then, is not whether some patients previously given a diagnosis do not seem to have it upon re-interview, but rather how many . How high the percentage should be before claiming over-diagnosis is a significant problem and a value judgment. But we think that an over-diagnosis rate of more than 50 percent crosses the clinical significance threshold.
Over-diagnosis of bipolar disorder has costs. Mood stabilizers are the treatment of choice, and, depending on the medication, they can produce potentially significant health complications affecting renal, endocrine, hepatic, immunologic, or metabolic function.
The impact of marketing efforts by pharmaceutical companies and publicity probably plays a role in the emerging tendency to over-diagnose bipolar disorder. Direct-to-consumer advertisements that refer individuals to screening questionnaires can result in patients suggesting to their doctors that they have bipolar disorder. We have seen evidence of this in our practice. This does not necessarily reflect a problem with the performance of a screening questionnaire, but rather how these scales are used. Screening questionnaires maximize sensitivity, at a cost of false positives, because it is presumed that they are followed by expert clinical evaluation. But insufficient diagnostic rigor can result in overdiagnosis.
Clinicians are inclined to diagnose disorders that they feel more comfortable treating. We believe that the increased availability of medications that have been approved for the treatment of bipolar disorder might be influencing clinicians who are unsure whether or not a patient has bipolar disorder or borderline personality disorder to err on the side of diagnosing the disorder that is responsive to medication.
This bias is reinforced by the marketing of pharmaceutical companies to physicians, which has emphasized research on delayed diagnosis and under-recognition of bipolar disorder, possibly sensitizing clinicians accordingly. The campaign against under-recognition has probably resulted in some anxious, agitated and/or irritable depressed patients who complain of insomnia and “racing thoughts” being misdiagnosed with bipolar disorder.
The results of our study are consistent with prior studies suggesting possible problems with the diagnosis of bipolar disorder. With the greater number of medications approved for the treatment of bipolar disorder, along with multiple reports cautioning clinicians against underdiagnosis, it appears that overdiagnosis has become a greater problem than underdiagnosis. Both can have negative consequences.
Mark Zimmerman is associate professor of psychiatry and human behavior at Brown Medical School.
COPYRIGHT: PROJECT SYNDICATE
US president-elect Donald Trump on Tuesday named US Representative Mike Waltz, a vocal supporter of arms sales to Taiwan who has called China an “existential threat,” as his national security advisor, and on Thursday named US Senator Marco Rubio, founding member of the Inter-Parliamentary Alliance on China — a global, cross-party alliance to address the challenges that China poses to the rules-based order — as his secretary of state. Trump’s appointments, including US Representative Elise Stefanik as US ambassador to the UN, who has been a strong supporter of Taiwan in the US Congress, and Robert Lighthizer as US trade
A nation has several pillars of national defense, among them are military strength, energy and food security, and national unity. Military strength is very much on the forefront of the debate, while several recent editorials have dealt with energy security. National unity and a sense of shared purpose — especially while a powerful, hostile state is becoming increasingly menacing — are problematic, and would continue to be until the nation’s schizophrenia is properly managed. The controversy over the past few days over former navy lieutenant commander Lu Li-shih’s (呂禮詩) usage of the term “our China” during an interview about his attendance
Following the BRICS summit held in Kazan, Russia, last month, media outlets circulated familiar narratives about Russia and China’s plans to dethrone the US dollar and build a BRICS-led global order. Each summit brings renewed buzz about a BRICS cross-border payment system designed to replace the SWIFT payment system, allowing members to trade without using US dollars. Articles often highlight the appeal of this concept to BRICS members — bypassing sanctions, reducing US dollar dependence and escaping US influence. They say that, if widely adopted, the US dollar could lose its global currency status. However, none of these articles provide
Bo Guagua (薄瓜瓜), the son of former Chinese Communist Party (CCP) Central Committee Politburo member and former Chongqing Municipal Communist Party secretary Bo Xilai (薄熙來), used his British passport to make a low-key entry into Taiwan on a flight originating in Canada. He is set to marry the granddaughter of former political heavyweight Hsu Wen-cheng (許文政), the founder of Luodong Poh-Ai Hospital in Yilan County’s Luodong Township (羅東). Bo Xilai is a former high-ranking CCP official who was once a challenger to Chinese President Xi Jinping (習近平) for the chairmanship of the CCP. That makes Bo Guagua a bona fide “third-generation red”